Targeting the fibroblast growth factor receptor (Fgfr) in advanced cholangiocarcinoma: Clinical trial progress and future considerations

Patrick C. Lee, Andrew Hendifar, Arsen Osipov, May Cho, Daneng Li, Jun Gong

Research output: Contribution to journalReview articlepeer-review

Abstract

Landmark molecular profiling efforts have identified multiple targetable alterations in cholangiocarcinoma. Among the molecular-driven subsets of cholangiocarcinoma, targeting the fi-broblast growth factor receptor (FGFR) has shown promise and represents the first targeted therapy to be approved in treatment-refractory, advanced cholangiocarcinoma. In this review, we provide an up-to-date overview of the clinical development of FGFR inhibitors in advanced cholangiocarci-noma. We review the FGFR pathway and discuss emerging issues including resistance to FGFR inhibitors. We end with a discussion on future considerations to optimize the potential of this class of therapeutics in advanced cholangiocarcinoma.

Original languageEnglish (US)
Article number1706
JournalCancers
Volume13
Issue number7
DOIs
StatePublished - Apr 1 2021

Keywords

  • Cholangiocarcinoma
  • Debio 1347
  • Derazantinib
  • Erdafitinib
  • Fibroblast growth factor receptor (FGFR)
  • Futibatinib
  • Infigratinib
  • Pemigatinib
  • TAS-120

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Targeting the fibroblast growth factor receptor (Fgfr) in advanced cholangiocarcinoma: Clinical trial progress and future considerations'. Together they form a unique fingerprint.

Cite this